Navigation Links
Nephros Reports First Quarter 2012 Financial Results
Date:5/15/2012

obtain appropriate or necessary regulatory approvals to achieve our business plan;
  • products that appeared promising to us in research or clinical trials may not demonstrate anticipated efficacy, safety or cost savings in subsequent pre-clinical or clinical trials;
  • we may encounter problems with our suppliers and manufacturers;
  • we may encounter unanticipated internal control deficiencies or weaknesses or ineffective disclosure controls and procedures;
  • HDF therapy may not be accepted in the United States and/or our technology and products may not be accepted in current or future target markets, which could lead to failure to achieve market penetration of our products;
  • we may not be able to effectively market products, including our HDF system
  • we may not be able to sell our chronic renal failure therapy or water filtration products at competitive prices or profitably;
  • we may not be able to secure or enforce adequate legal protection, including patent protection, for our products; and
  • we may not be able to achieve sales growth in key geographic markets.
  • More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements, including the forward-looking statements in this press release, is set forth in our filings with the SEC, including our Annual Report on Form 10-K for the fiscal year ended December 31, 2011, and our other periodic reports filed with the SEC. We urge investors and security holders to read those documents free of charge at the SEC's web site at www.sec.gov. We do not undertake to publicly update or revise our forward-looking statements as a result of new information, future events or otherwise, except as required by law.NEPHROS, INC. AND SUBSIDIARYCONDENSED CONSOLIDATED BALANCE SHEETS(In thousands)March 31, 2012December 31, 2011(Unaudited)(Audited)Assets:
    '/>"/>

    SOURCE Nephros, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8

    Related medicine technology :

    1. Nephros Completes Pivotal U.S. Clinical Trial for its Hemodiafiltration Products
    2. Nephros Reports 2009 Third Quarter Financial Results
    3. Nephros Signs Canadian Distribution Agreement with Bellco Health Care Inc.
    4. Nephros Signs Development Agreement with STERIS
    5. Nephros Reports 2010 First Quarter Financial Results
    6. Nephros and AmeriWater Announce Dual Stage Ultrafilters to be a Standard Component of MRO Series Water Treatment Systems
    7. Nephros Receives Formal Response from FDA for 510(k) Application for Hemodiafiltration System
    8. Nephros Reports 2010 Second Quarter Financial Results
    9. Nephros Completes Bridge Financing and Announces Stockholder Rights Offering
    10. Nephros Reports 2010 Third Quarter Financial Results
    11. Nephros Rights Offering Registration Statement Declared Effective
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/30/2014)...  PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI ... the Jefferies 2014 Boston Healthcare Summit next week in ... on August 6, 2014 and will not be webcast. ... BioPharma manages a portfolio of patents and royalty assets, ... patents and license agreements with various biotechnology and pharmaceutical ...
    (Date:7/30/2014)... Die Apex Medical Corporation (Apex, ... Atemtherapie- und Druckzonenprodukte, gibt bekannt, dass sie ... anfechten werden. Dieses hat entschieden, dass die ... ResMed verletze. Apex weist darauf hin, dass ... Patente von ResMed Anfechtungen wegen Nichtigkeit eingeleitet ...
    (Date:7/29/2014)... 29, 2014 /PRNewswire-iReach/ -- The global microbial identification ... methods, applications, end users, and geographies. Genotypic technology ... microbial identification market. This favorable growth is attributed ... and the time required for microbial identification along ... Furthermore, genotypic methods have high applications in clinical ...
    Breaking Medicine Technology:PDL BioPharma to Participate in Jefferies 2014 Boston Healthcare Summit 2Apex setzt seinen Kampf gegen Patente für einen freien Wettbewerb fort 2Apex setzt seinen Kampf gegen Patente für einen freien Wettbewerb fort 3Microbial Identification Market Growing at 5.9% CAGR to 2019: Global Forecast in New Research Report Available at ReportsnReports.com 2Microbial Identification Market Growing at 5.9% CAGR to 2019: Global Forecast in New Research Report Available at ReportsnReports.com 3Microbial Identification Market Growing at 5.9% CAGR to 2019: Global Forecast in New Research Report Available at ReportsnReports.com 4Microbial Identification Market Growing at 5.9% CAGR to 2019: Global Forecast in New Research Report Available at ReportsnReports.com 5Microbial Identification Market Growing at 5.9% CAGR to 2019: Global Forecast in New Research Report Available at ReportsnReports.com 6
    ... , TAMPA, Fla. , April 26 ... today that Zirgan™ (ganciclovir ophthalmic gel) 0.15% is now commercially ... Drug Administration in September 2009 , is a topical ... (dendritic ulcers).   , ...
    ... April 26 Aton Pharma, Inc., a ... acquired the U.S. marketing rights to LODOSYN® (carbidopa) tablets ... use with carbidopa-levodopa or with levodopa in the treatment ... administration of lower doses of levodopa with reduced nausea ...
    Cached Medicine Technology:Sirion Therapeutics Announces Availability of Zirgan(TM) (ganciclovir ophthalmic gel) 0.15% for Ocular Herpes 2Sirion Therapeutics Announces Availability of Zirgan(TM) (ganciclovir ophthalmic gel) 0.15% for Ocular Herpes 3Aton Pharma Acquires Parkinson's Drug LODOSYN(R) (carbidopa) 2Aton Pharma Acquires Parkinson's Drug LODOSYN(R) (carbidopa) 3Aton Pharma Acquires Parkinson's Drug LODOSYN(R) (carbidopa) 4
    (Date:7/30/2014)... ... ... ... , UCLA researchers interviewed people with diverticulitis and confirmed that many suffer psychological and physical symptoms long after their ... UCLA team led by Dr. Brennan Spiegel interviewed patients in great detail about the symptoms they experience weeks, months or even years ...
    (Date:7/30/2014)... The Ehlers-Danlos National Foundation (EDNF) is pleased to ... will serve as chair. The board was voted upon ... Conference in Houston, Texas July 10-12. , “The ... us. From the rollout of the first EDNF Center ... Medical Center to our September physicians conference to a ...
    (Date:7/30/2014)... OR (PRWEB) July 30, 2014 LTC Consumer, ... evaluate long term care insurance, features an Instant Quote tool ... Director and co-founder of LTC Consumer. Quotes are free and ... a click in only seven areas – including age, gender, ... on screen within seconds (you don’t need to enter any ...
    (Date:7/30/2014)... The American Telemedicine Association (ATA) today ... (R-MS) and Roger Wicker (R-MS) for their efforts ... Medicare, Medicaid and Federal Communications Commission programs. , ... the Telehealth Enhancement Act as S. 2662, a ... introduced by Rep. Gregg Harper (R-MS) which already ...
    (Date:7/30/2014)... July 30, 2014 Hospitals continually ... quality of care that their practitioners provide. During ... Andrew Rowe, discussed the importance of establishing effective ... physician performance and quality of care. , ... evaluation, Mr. Rowe elaborated on setting performance expectations, ...
    Breaking Medicine News(10 mins):Health News:Diverticulitis patients reveal psychological, physical symptoms long after acute attacks 2Health News:Diverticulitis patients reveal psychological, physical symptoms long after acute attacks 3Health News:Ehlers-Danlos National Foundation Announces New Leadership 2Health News:LTC Consumer Launches Online Tool for Getting Instant Long Term Care Insurance Estimates 2Health News:ATA Applauds Senators’ Push for Federal Telemedicine Improvements 2Health News:AllMed Webinar Helps Hospitals Optimize Practitioner Evaluations in Peer Review 2Health News:AllMed Webinar Helps Hospitals Optimize Practitioner Evaluations in Peer Review 3
    ... risk factors are known to play a role in the ... known about the effect of body mass index and clustering ... ,Recently a study, published in the October issue of ... the relation between midlife body mass index and clustering of ...
    ... dysfunction (ED) is the inability of a man to achieve ... the needs of his partner. Most men experience this at ... are not psychologically affected by it. Some men, however, experience ... ,According to a new study in the October ...
    ... HIV vaccine is being jointly developed by Vical Pharmaceuticals and ... was developed by the scientistis in NIH and the Federal ... inserting the HIV genes//. ,Vical Inc. is a ... DNA delivery system, last month Vical has agreed to grant ...
    ... has been set up in Pakistani Kashmir to provide surgery ... ,The hospital was erected in just 2 hours//. The unit ... paramedical staff. The mobile unit was transported to Muzaffarabad, the ... medical facility has proved to be a boon to the ...
    ... up lately and this is causing harm to the patients ... tests, says a new study that was published online today ... of the University of Pittsburgh and colleagues studied 24,000 cases ... that erroneous diagnosis was made in nearly 1,300 cases. The ...
    ... is the most common cause of chronic liver disease ... NAFLD is currently available//. Understanding the specific effects of ... is important for patient counseling as well as for ... these issues, researchers from Mayo Clinic College of Medicine, ...
    Cached Medicine News:Health News:Erectile dysfunction: an early warning sign of clinically silent coronary artery disease? 2Health News:Weight reduction by 5% may help in treating nonalcoholic fatty liver disease 2
    ... 20-year history, the VOYAGER RX Dilatation Catheter ... outcomes. It combines a new low profile, ... shaft,more flexible markers, and short taper balloon ... tortuous anatomy with even greater confidence, opening ...
    ... technology developed over Guidants 20-year history, the ... foundation for successful treatment outcomes. It combines ... with a lower profile shaft,more flexible markers, ... can cross tight and tortuous anatomy with ...
    ... Coat-A-Count AFP IRMA,is an ... measurement of,alpha-fetoprotein (AFP) in serum. ... vitro use in either of,two ... aid in the,management of patients ...
    Enzyme immunoassay for the quantitative determination of ovarian cancer antigen CA125 in human serum...
    Medicine Products: